Published in Cancer Weekly, May 4th, 2004
INGN 241, a product candidate designed to deliver the MDA-7/IL-24 gene to tumor cells, is being developed by Introgen Therapeutics, Inc., (INGN) and is in phase I and phase II clinical trials in a variety of cancers.
The data were generated in an ongoing collaboration between researchers at Introgen and the University of Texas M.D. Anderson Cancer Center.
Dr. Sunil Chada, Introgen's director of research and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.